Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to decode which lung test best predicts breathing relief

NCT ID NCT07364188

Knowledge-focused Sponsor: Allergi- og Lungeklinikken, Elsinore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 120 adults with asthma or COPD to see how changes in lung function tests (spirometry and impulse oscillometry) relate to how much their breathing improves after using a bronchodilator. Participants will take a standard reversibility test and report their symptom relief on a scale. The goal is to find the smallest meaningful change in these tests that matches real-world breathing improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bronchodilator (beta-2-agonist)
What this could lead to
If successful, this study could help doctors better understand which lung function tests best reflect symptom relief after using a bronchodilator.
What could go wrong
This is an observational study that does not test a new treatment. Results may not change current practice or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

referred to Allergy and Lung Clinic Elsinore, Denmark for evaluation of Asthma and COPD (obstructive lung disease)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both asthma and COPD patients: 1. Written informed consent. 2. FEV1/Forced Vital Capacity (FVC) \<0.7 at baseline (7) 3. Visual Analog Scale (VAS) dyspnea score ≥10 (0-100, 100 max) (25,26). * Asthma: Doctor diagnosed asthma 1\. less than 10 packyears. * COPD: Doctor diagnosed COPD with FEV1/FVC \<0.7 post-bronchodilation 1. Smokers or ex-smokers with ≥10 packyears Exclusion Criteria: * Patients aged less than 18 years old. * Not able to perform spirometry or impulse oscillometry. * Cognitive disorders and not able to answer Asthma Control Questionnaire (ACQ), VAS dyspnea score, and COPD Assessment Test (CAT) score (25-28). * Short-acting beta-agonists 6 h, long-acting beta-agonists 2 days, short-acting anti-muscarinic agent 12 h, Long-acting anti-muscarinic agents 2 days. * Comorbidities with significant influence on dyspnea eg. bronchiectasis, ILS, mb. Cordis, lung resection, anemia, and active malignant disease * BMI ≥40 kg/m2.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma bronchiale are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma bronchiale Bronchodilation COPD Impedance Small airways disease Spirometry

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.